Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Lipocine Inc. (LPCN)

0.45   0.015 (3.35%) 10-02 21:07
Open: 0.43 Pre. Close: 0.4354
High: 0.4594 Low: 0.43
Volume: 91,924 Market Cap: 40(M)
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.46 - 0.46 0.46 - 0.46
Low: 0.43 - 0.43 0.43 - 0.43
Close: 0.45 - 0.45 0.45 - 0.45

Technical analysis

as of: 2022-09-30 4:29:41 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 0.6     One year: 0.71
Support: Support1: 0.36    Support2: 0.29
Resistance: Resistance1: 0.51    Resistance2: 0.61
Pivot: 0.5
Moving Average: MA(5): 0.42     MA(20): 0.51
MA(100): 0.72     MA(250): 0.96
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 31.8     %D(3): 24.1
RSI: RSI(14): 35.9
52-week: High: 1.88  Low: 0.36
Average Vol(K): 3-Month: 266 (K)  10-Days: 319 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ LPCN ] has closed above bottom band by 28.3%. Bollinger Bands are 60.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Headline News

Tue, 27 Sep 2022
Other news to note for Sept. 27, 2022 | BioWorld - BioWorld Online

Tue, 27 Sep 2022
Lipocine (LPCN) Stock: Why It Fell 10.41% - Pulse 2.0

Thu, 15 Sep 2022
Lipocine Announces Favorable Regulatory Pathway On LPCN 1154 For Post-Partum Depression - Nasdaq

Thu, 15 Sep 2022
Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD) - Yahoo Finance

Thu, 11 Aug 2022
Further weakness as Lipocine (NASDAQ:LPCN) drops 11% this week, taking five-year losses to 83% - Simply Wall St

Mon, 08 Aug 2022
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022 - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 86 (M)
% Held by Insiders 2.5 (%)
% Held by Institutions 13.6 (%)
Shares Short 2,250 (K)
Shares Short P.Month 2,340 (K)

Stock Financials

EPS -0.38
EPS Est Next Qtl -0.19
EPS Est This Year -0.96
EPS Est Next Year -0.73
Book Value (p.s.) 0.21
Profit Margin (%) -4.7
Operating Margin (%) 19.3
Return on Assets (ttm) 3.9
Return on Equity (ttm) -1.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share -242.3
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -4 (M)
Levered Free Cash Flow 2 (M)

Stock Valuations

PE Ratio -1.19
PEG Ratio 0
Price to Book value 2.04
Price to Sales -0.01
Price to Cash Flow -0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.